NCT Number: NCT00214734
ADVATE Post Authorization Safety Surveillance
The primary objective of this post-authorization safety surveillance is to measure the incidence of adverse events that are at least possibly related to ADVATE use, in subjects receiving ADVATE in routine clinical practice.
Looking for future studies?
Notify MeKey information
Conditions
Sex eligibility
Male
Study type
Observational
Primary location
PHOENIX CHILDRENS Hospital, Phoenix, Arizona, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Subject has moderate or severe hemophilia A (baseline FVIII less than or equal to 5%)
- Subject currently has no measurable FVIII inhibitor titer greater than or equal to 1 BU (Bethesda or Nijmegen method)
- Subject has been prescribed ADVATE by their treating physician
- Subject may be of any age
- Subject or parent/legally authorized representative has provided written informed consent
Exclusion criteria
- None
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Baxalta now part of Shire
Industry
Collaborators
- Baxter BioScience
Registry information
Official study title
Evaluation of Safety, Efficacy, and Immunogenicity of ADVATE in Hemophilia A- An ADVATE Post-authorization Safety Surveillance (PASS) Study
Important dates
- Study start
- 2004
- Study completion
- 2007
- First posted
- Sep 22, 2005
- Registry last updated
- Mar 17, 2021
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood
NCT05147662
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Orlando, Florida, United States
View Trial DetailsPharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia A
NCT06579144
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Sofia, Bulgaria
View Trial DetailsEfficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
NCT03315455
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Beijing, China
View Trial DetailsA Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Emicizumab in Participants With Mild or Moderate Hemophilia A Without FVIII Inhibitors
NCT04158648
Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited
Los Angeles, California, United States
View Trial Details